Leading experts in the field of myeloma, Keith Stewart and Gareth Morgan, share highlights from day one of the Myeloma 2022 meeting. They discuss updates in measurable residual disease (MRD) and prognosis, antibody therapy for amyloidosis, new drugs, immune system drugs, single cell sequencing, and the potential of genomics in myeloma and cancer treatment.